<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1395w–3a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1395w–3a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1395w–3a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1395w_3a"><akn:num>1395w–3a</akn:num><akn:heading>Use of average sales price payment methodology</akn:heading><akn:content><akn:p>§ 1395w–3a. Use of average sales price payment methodology(a) Application(1) In generalExcept as provided in paragraph (2), this section shall apply to payment for drugs and biologicals that are described in section 1395u(o)(1)(C) of this title and that are furnished on or after January 1, 2005.


(2) ElectionThis section shall not apply in the case of a physician who elects under subsection (a)(1)(A)(ii) of section 1395w–3b of this title for that section to apply instead of this section for the payment for drugs and biologicals.



(b) Payment amount(1) In generalSubject to paragraph (7) and subsections (d)(3)(C) and (e), the amount of payment determined under this section for the billing and payment code for a drug or biological (based on a minimum dosage unit) is, subject to applicable deductible and coinsurance—(A) in the case of a multiple source drug (as defined in subsection (c)(6)(C)), 106 percent of the amount determined under paragraph (3) for a multiple source drug furnished before April 1, 2008, or 106 percent of the amount determined under paragraph (6) for a multiple source drug furnished on or after April 1, 2008;

(B) in the case of a single source drug or biological (as defined in subsection (c)(6)(D)), 106 percent of the amount determined under paragraph (4) or in the case of such a drug or biological product that is a selected drug (as referred to in section 1320f–1(c) of this title), with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), 106 percent of the maximum fair price (as defined in section 1320f(c)(3) of this title) applicable for such drug and a year during such period; or

(C) in the case of a biosimilar biological product (as defined in subsection (c)(6)(H)), the amount determined under paragraph (8).


(2) Specification of unit(A) Specification by manufacturerThe manufacturer of a drug or biological shall specify the unit associated with each National Drug Code (including package size) as part </akn:p></akn:content><akn:subsection eId="subsec_1395w_3a_a"><akn:num>(a)</akn:num><akn:heading>Application</akn:heading><akn:content><akn:p>(a) Application</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_b"><akn:num>(b)</akn:num><akn:heading>Payment amount</akn:heading><akn:content><akn:p>(b) Payment amount</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_c"><akn:num>(c)</akn:num><akn:heading>Manufacturer’s average sales price</akn:heading><akn:content><akn:p>(c) Manufacturer’s average sales price</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_d"><akn:num>(d)</akn:num><akn:heading>Monitoring of market prices</akn:heading><akn:content><akn:p>(d) Monitoring of market prices</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_e"><akn:num>(e)</akn:num><akn:heading>Authority to use alternative payment in response to public health emergency</akn:heading><akn:content><akn:p>(e) Authority to use alternative payment in response to public health emergency In the case of a public health emergency under section 247d of this title in which there is a documented inability to access drugs and biologicals, and a concomitant increase in the price,11 So in original. The comma probably should not appear. of a drug or biological which is not reflected in the manufacturer’s average sales price for one or more quarters, the Secretary may use the wholesale acquisition cost (or other reasonable measure of drug or biological price) instead of the manufacturer’s average sales price for such quarters and for subsequent quarters until the price and availability of the drug or biological has stabilized and is substantially reflected in the applicable manufacturer’s average sales price.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_f"><akn:num>(f)</akn:num><akn:heading>Quarterly report on average sales price</akn:heading><akn:content><akn:p>(f) Quarterly report on average sales price</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_g"><akn:num>(g)</akn:num><akn:heading>Payment adjustment for certain drugs for which there is a self-administered NDC</akn:heading><akn:content><akn:p>(g) Payment adjustment for certain drugs for which there is a self-administered NDC</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_h"><akn:num>(h)</akn:num><akn:heading>Refund for certain discarded single-dose container or single-use package drugs</akn:heading><akn:content><akn:p>(h) Refund for certain discarded single-dose container or single-use package drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_i"><akn:num>(i)</akn:num><akn:heading>Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation</akn:heading><akn:content><akn:p>(i) Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_3a_j"><akn:num>(j)</akn:num><akn:heading>Judicial review</akn:heading><akn:content><akn:p>(j) Judicial review There shall be no administrative or judicial review under section 1395ff of this title, section 1395oo of this title, or otherwise, of—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>